Navigation Links
U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta
Date:4/27/2011

INDIANAPOLIS, April 27, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has issued an order that prohibits the remaining defendants in the Cymbalta® (duloxetine hydrochloride) patent litigation from selling a generic duloxetine product in the United States during the term of the Cymbalta compound patent. The patent provides protection for Cymbalta until at least June of 2013.  

The order came in the case of Eli Lilly and Company v. Wockhardt Limited, et al. The Court had initially entered final judgment against Wockhardt on March 21, 2011.  As part of today's Court order, the defendants are further required to notify the Food and Drug Administration that they are no longer seeking approval for a generic duloxetine product during the patent term. In light of the parties' stipulation to the Court's order, the litigation has been dismissed and no appeal is possible.  

"We are very pleased with the District Court's order that effectively maintains U.S. exclusivity for Cymbalta throughout its patented life," said Robert A. Armitage, senior vice president and general counsel for Lilly. "Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Cymbalta patent litigation. These statements are based on management's current expectations but actual results may differ materially. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Cymbalta® (duloxetine hydrochloride, Lilly)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
2. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
3. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
4. Sensipar® Patents Upheld By District Court
5. Winner Medical Honored with Shenzhen Baoan District Quality Award
6. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
7. German District Court Finds RENASYS™ GO NPWT System Non-infringing
8. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
9. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
10. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
11. McDonald Hopkins Law Firm Alert: Recent Court of Appeals Decision Highlights the Need to Properly Define the Role of Sales Representatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Research and Markets has announced the ... their offering. ... R&D Drug Pipeline Database: 1-Year ... Drug Pipeline Database provides 24/7 online access to information about more ... and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder mundial ... el INSTI HIV Self Test , a los miembros de la Kenya ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue ...
(Date:12/2/2016)...  LifeVac, the revolutionary device that has successfully rescued ... Training and Support Services (ERTSS) training programs. ... part of the ERTSS mission to save lives," said ... "Having an established network of expert trainers demonstrating how ... our efforts to spread LifeVac,s message that choking deaths ...
Breaking Medicine Technology:
(Date:12/2/2016)... AL (PRWEB) , ... December 02, 2016 , ... ... from across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF ... Schmitz, will help provide scholarship funds for area students and operating support to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related ... those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, which ... give parents and other caregivers the opportunity to share stories and advice, seek help, ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... high school and while 84 percent of parents report speaking with their child about ... pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
Breaking Medicine News(10 mins):